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Venous thromboembolism (VTE) is a common complication in patients with malignant disease. First recognised by Bouillard in 1823
and later described by Trousseau in 1844, multiple studies have since provided considerable evidence for a clinical association
between VTE and cancer. Across all cancers, the risk for VTE is elevated 7-fold; in certain malignancies, the risk for VTE may be
increased up to 28-fold. Venous thromboembolism is the second leading cause of death in patients with cancer; among survivors,
complications commonly include recurrent VTE and post-thrombotic syndrome, and (more rarely) chronic thromboembolic
pulmonary hypertension, which are costly, and have a profound impact on the patient’s quality of life. Tumour cells can activate blood
coagulation through multiple mechanisms, including production of procoagulant, fibrinolytic, and proaggregating activities, release of
proinflammatory and proangiogenic cytokines, and interacting directly with host vascular and blood cells (e.g., endothelial cells,
leukocytes, and platelets) through adhesion molecules. Increasing evidence suggests that elements of the haemostatic system also
have a direct role in eliciting or enhancing angiogenesis, cell survival, and metastasis. Despite the problem posed by VTE in the setting
of cancer, it is evident that a significant number of oncologists do not recognise the link between cancer, its treatment, and
thrombogenesis. On 22 May 2009, a group of UK-based physicians met in London, UK, to evaluate recent data on cancer thrombosis.
This article (1 of 4) briefly reviews key data on the epidemiology and pathophysiology of VTE as a context for a discussion and
consensus statement developed by meeting attendees, on the implications of this information for UK clinical practice.
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The relationship between cancer and venous thromboembolism
(VTE) has been recognised for almost two centuries. Historically,
the French physician, Armand Trousseau, is credited with initially
describing the relationship between VTE and cancer in a seminal
book published in 1865 (Trousseau, 1865); however, it has since
been recognised that the first description of deep vein thrombosis
(DVT) in patients with cancer was made by Bouillard in 1823–42
years earlier than Trousseau (Bouillard and Bouillaud, 1823). Since
the time of Bouillard and Trousseau, multiple studies have
provided considerable evidence for a two-way clinical association
between VTE and cancer: contemporary studies, such as the 2005
MEGA (Multiple Environmental and Genetic Assessment) study,
clearly indicate that patients with cancer have an elevated risk for
VTE, particularly during the first few months after diagnosis and
in the presence of distant metastases (Blom et al, 2005).
Conversely, the risk for cancer seems elevated for at least 2 years
after a first episode of idiopathic VTE (Murchison et al, 2004).
Cancer is responsible for 18% of all cases of incident VTE.
Across all patients with cancer, the risk for VTE is elevated 7-fold;
in certain malignancies, the risk for VTE may be increased up to
28-fold (Blom et al, 2005). In patients with cancer, VTE is the
second leading cause of death; in fact, of every seven patients with
cancer who die while hospitalised, one will die of pulmonary
embolism (PE). Even among patients who survive an episode of
VTE, complications such as recurrent VTE, post-thrombotic
syndrome, and chronic thromboembolic pulmonary hypertension
are common, costly, and have a profound impact on the patient’s
quality of life.
Despite the problem posed by VTE in the setting of cancer, it is
evident that a notable proportion of oncologists do not recognise
the link between cancer, its treatment, and thrombogenesis.
Moreover, many do not recognise the need for thromboprophy-
laxis in selected patient populations. A small 2003 questionnaire
survey, conducted in northern England, examined prophylaxis for
VTE during treatment for cancer (Kirwan et al, 2003). Among
oncologists who responded, over 27% believed that their patients
were not at risk for VTE. This response was independent of the
type of tumour treated (Kirwan et al, 2003). It is noteworthy that
over 60% of respondents did not believe that hormone therapy or
chemotherapy increased risk for VTE (Kirwan et al, 2003), and
approximately 80% did not use thromboprophylaxis routines in
chemotherapy or hormone therapy. Similarly, the FRONTLINE
survey – a comprehensive global survey of thrombosis and cancer
– found that 50% of surgical cancer patients and 95% of medical
patients do not use thromboprophylaxis (Kakkar et al, 2003).
On 22 May 2009, a small group of UK-based health-care
providers gathered in London, UK, to evaluate the most recent
data on cancer-associated thrombosis and its implications for UK
clinical practice. This article – 1 of 4 covering broad topics in *Correspondence: Dr S Noble; E-mail: simon.noble@gwent.wales.nhs.uk
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www.bjcancer.comcancer thrombosis – includes a brief review of key data on the
epidemiology and pathophysiology of VTE to provide context for a
discussion surrounding these data and a consensus statement,
developed by meeting attendees, on the implications of this
information for UK clinical practice.
THE RISK FOR DVT AND PE IN PATIENTS WITH
CANCER
A large, population-based, case–control study – the MEGA study –
found that patients with cancer have a significantly increased risk
for VTE, particularly during the first few months after diagnosis
and in the presence of distant metastases (Blom et al, 2005).
Among the cohort examined in this study, which comprised over
3200 patients with a first DVT of the leg, PE, or both, the overall
risk for VTE was elevated by 7-fold in patients, compared with a
malignancy (Blom et al, 2005), with the most profound increases in
risk seen in patients with haematological malignancies (28-fold
increased risk), lung cancer (22-fold), gastrointestinal cancer
(20-fold), or with distant metastases (19.8-fold) (Blom et al,
2005). The risk for VTE was 54-fold higher from 0 to 3 months
after diagnosis, rapidly declining thereafter to 14-fold higher at
3–12 months and 3.6 at 1–3 years after diagnosis. Notably,
however, the risk for VTE remained appreciably elevated up to
15 years after initial diagnosis (Blom et al, 2005).
Epidemiological studies suggest that haematological, lung, and
gastrointestinal cancers, as broad diagnostic categories, are
associated with a substantial risk for VTE. Significant efforts have
been made to further delineate the cancer types that are associated
with the highest risk for thrombotic events. In 1999, Levitan and
colleagues assessed the rate of DVT/PE in a population of 41.2
million US Medicare patients (primarily aged X65 years) initially
admitted with a malignancy (Levitan et al, 1999). As shown in
Table 1, malignancies associated with the highest incidence
of DVT/PE include kidney, stomach, pancreas, brain, and ovarian,
as well as lymphoma. In contrast, cancers of the head and neck,
bladder, breast, oesophagus, uterus, and cervix are associated with
relatively low rates of DVT/PE.
The incidence of VTE in hospitalised patients with cancer
increased sharply between 1979 and 1999 (Figure 1) (Stein et al,
2006). This increase has been substantially sharper than the rise
in incidence observed among hospitalised patients who do not
have cancer. These data suggest that improved diagnostic
modalities are only partly responsible for changes over time in
the incidence of VTE in patients with malignancies. Similarly,
Khorana et al (2006) found that there was a 36% increase in
venous events among hospitalised neutropenic cancer patients
between 1995 and 2002.
The data summarised above clearly indicate that the risk for
VTE is elevated appreciably in patients with cancer. Data also
suggest that patients with cancer undergoing surgical procedures
have an approximately two-fold increased risk for developing VTE
compared with those without cancer (White et al, 2005).
Impact of cancer therapy
Cancer therapy itself has been shown to increase the risk for VTE,
whether it be chemotherapy, antiangiogenic therapy, or hormonal
therapy. With regard to chemotherapy, Blom et al (2004)
conducted a prospective, multicentre, observational study in
which the overall incidence of VTE in an ambulatory population
starting a new chemotherapy was 1.93% over a median follow-up
period of 2.4 months. The rate of VTE observed in this study (0.8%
per month) was substantially in excess of the estimated rate of
approximately 0.04% per month for the entire cancer population.
As noted earlier, lung cancer is associated with a 20-fold increased
risk for thrombosis. Data suggest that chemotherapy is associated
with a three-fold increased risk for VTE over and above this
already elevated rate, with further increases with time on
chemotherapy (Blom et al, 2004).
Antiangiogenic chemotherapy
Antiangiogenic therapies can have significant effects on VTE
incidence. When used alone, the rate of VTE among thalidomide
patients is o2%. However, when combined with dexamethasone
or other chemotherapies, the rate of VTE increases to 12–26%
(Barlogie et al, 2001; Zangari et al, 2001; Cavo et al, 2002;
Rajkumar et al, 2006). Some data indicate that lenalidomide may
be associated with a somewhat lower incidence of VTE,
particularly when combined with aspirin (Rajkumar et al,
2006). Some early data suggested that the monoclonal antibody,
bevacizumab, may be associated with increased risk for VTE
(Shah et al, 2005); some recent trials indicate that bevacizumab in
the context of contemporary chemotherapy regimens is not
associated with significant elevations in risk (Hurwitz et al,
2004). In contrast, a more recent meta-analysis of 15 trials
conducted in patients with advanced solid tumours (N¼7956)
found that the overall incidence of all-grade and high-grade VTE
was 11.9 and 6.3%, respectively (Nalluri et al, 2008). Patients who
received bevacizumab in these trials had a significantly increased
risk for VTE, with a relative risk of 1.33. Risk for VTE was not dose
dependent: at a low bevacizumab dosage of 2.5mgkg
 1 per week,
the relative risk for VTE was 1.31 (P¼0.007); at a high dosage of
Table 1 Rates of DVT/PE in different malignancies
Site
Rate of DVT/PE per
10000 patients
Head/neck 16
Bladder 22
Breast 22
Oesophagus 43
Uterus 44
Cervix 49
Prostate 55
Lung 61
Rectal 62
Liver 69
Colon 76
Leukaemia 81
Renal 84
Stomach 85
Lymphoma 96
Pancreas 110
Brain 117
Ovary 120
An analysis of 41.2 million US Medicare (age X65) patients admitted to the hospital
with a malignancy (Levitan et al, 1999).
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Figure 1 Increased VTE prevalence over time in patients with cancer,
but not in those without cancer (Stein et al, 2006).
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 1 per week, the relative risk was identical at 1.31
(P¼0.04).
Hormonal therapy
Adjuvant hormonal therapy with tamoxifen is also recognised to
increase the risk for VTE (Saphner et al, 1991). In a study on 2600
patients with breast cancer enrolled in the Eastern Cooperative
Oncology Group adjuvant studies, the frequency of venous and
arterial thrombosis was significantly higher among adjuvant
therapy patients compared with observation-only patients (5.4 vs
1.6%; P¼0.0002). Notably, the risk for VTE seems to be reduced
with aromatase inhibitors compared with tamoxifen (Howell et al,
2005). In the Arimidex, Tamoxifen alone, or in Combination
(ATAC) study, the rate of VTE after 68 months of follow-up was
4.5% in patients who received tamoxifen, compared with 2.8% in
those who received anastrozole.
Erythropoietin-stimulating agents
A systematic review of randomised trials suggests that these
agents (e.g., epoetin a and b; darbepoetin a) are associated
with an approximately 67% increased risk for VTE (Bohlius et al,
2006).
Mode of administration
Central venous catheters, in the form of surgically tunnelled
catheters or totally implanted venous access devices, are being
increasingly used in clinical practice. Although these devices have
revolutionised the clinical management of patients with cancer,
they are associated with considerable morbidity, occasional
mortality, and the loss of catheters. Indwelling catheters have
been shown to be associated with a 27–67% incidence of catheter-
associated DVT, which is primarily asymptomatic (Monreal et al,
1994; Prandoni et al, 1997a; Verso and Agnelli, 2003). Pulmonary
embolism is observed in 15–36% of patients with symptomatic
catheter-associated DVT. The wide variability in the incidence of
catheter-related thrombosis may be due to differences in catheter
type, position, duration of insertion, type of malignancy, and use
of different chemotherapeutic agents. It is important to note that –
because catheters are deep in the mediastinum – thrombosis is
frequently not discovered until late in its course, magnifying the
consequences of DVT in these patients and complicating treatment
considerably.
CONSEQUENCES OF DVT AND PE
Venous thromboembolism is associated with considerable mor-
tality. Khorana et al (2006) estimated the incidence of VTE in
hospitalised cancer patients actively receiving therapy. In-hospital
mortality was substantially higher among patients with VTE
compared with patients without such a diagnosis (OR¼2.01;
Po0.0001), with a somewhat greater risk for death among patients
with metastatic disease (OR¼2.06; Po0.0001) than in those with
non-metastatic disease (OR¼1.62; Po0.0001).
The @RISTOS project prospectively examined the epidemiology
of VTE after cancer surgery. In this study, patients were assessed
for clinically overt VTE occurring up to 30±5 days (or more if the
hospital stay was 435 days) (Agnelli et al, 2006). Among the total
population of 2373 patients who underwent surgery, the overall
death rate was 1.72%. Of these, death was caused by VTE in nearly
half (46.3%) of the cases, making it the most common single cause
of death at 30 days after surgery.
Beyond mortality, VTE is associated with a number of
conditions that can severely compromise patients’ quality of life
and add tremendously to the burden attributable to this condition,
including recurrent VTE, post-thrombotic syndrome, and
pulmonary hypertension.
Recurrent VTE and bleeding
Venous thromboembolism is now considered to be a chronic
disease, in that the risk for recurrence persists for many years after
the initial event. A prospective follow-up study, conducted by
Prandoni and colleagues and published in 2002, evaluated the risk
for recurrent VTE or bleeding during anticoagulant treatment in
842 patients with DVT with and without cancer who were receiving
anticoagulant therapy (Prandoni et al, 2002). Among the 181
patients included in the study who had known cancer at study
entry, the cumulative incidence of recurrent VTE was 20.7%,
compared with 6.8% among those without cancer (hazard ratio 3.2;
Figure 2A). The incidence of major bleeding was also increased
2.2-fold among patients with cancer (12.4 vs 4.9%) (Figure 2B).
Both recurrence and bleeding were related to cancer severity,
occurred primarily during the first month of anticoagulant
therapy, and were not adequately explained by over- or under-
coagulation. These data suggest that many patients with cancer
with an initial episode of VTE may require extended – and
sometimes lifelong – antithrombotic therapy; however, the risks
for bleeding must be carefully weighed against the thrombopro-
phylactic benefit associated with treatment, and patients must be
closely monitored for symptoms of bleeding, even when in the
therapeutic range for a given anticoagulant.
Post-thrombotic syndrome
Few data are available on the incidence of post-thrombotic
syndrome in patients with cancer; however, approximately 30%
of patients with DVT overall subsequently develop this chronic,
frequently disabling condition within 5 years of an incident, of
whom 8.1% will have severe post-thrombotic manifestations
(Prandoni et al, 1997b). Symptoms of post-thrombotic syndrome
include debilitating leg pain, swelling, and fibrosis. Severe
manifestations may result in leg ulceration, limitation in mobility,
and the need for long-term nursing care.
Pulmonary hypertension
Pulmonary hypertension is a life-threatening condition associated
with fatigue, chest pain, peripheral swelling, and increased
mortality. Recent studies suggest that 4–5% of patients develop
pulmonary hypertension p2 years after symptomatic PE (Pengo
et al, 2004).
THE PATHOPHYSIOLOGY OF VTE IN CANCER
Overview of the haemostatic system
The haemostatic system is a complex, multifaceted host defence
mechanism that evolved to protect the integrity of the vascular
system. It works in coordination with the mechanisms of
inflammation and repair, producing a coordinated response.
Haemostatic systems are normally quiescent and are only activated
after injury. Ultimately, the coordinated haemostatic response
results in the production of a platelet plug, fibrin-based clot,
deposition of white cells at the point of injury, and activation of
inflammatory and repair processes.
After injury and vessel vasoconstriction, reduced blood flow
permits contact activation of platelets (Figure 3). Subsequently,
platelets adhere to exposed connective tissue (mediated in part by
the von Willebrand factor) and release an array of vasoactive
proteins that interact with other platelets and leukocytes,
enhancing platelet activation and leading to the formation of
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time, the vascular endothelium moves from its resting phase
(anticoagulant) to a more active (procoagulant) and repair phase.
In concert with these cellular changes, inactive plasma coagulation
factors are converted to their respective active species by cleavage
at internal peptide bonds. In sequence, these active factors
generate thrombin, which leads to the formation of fibrin from
fibrinogen (to stabilise the platelet plug), cross-linking of fibrin
(through activation of factor XIII), further activation of platelets,
and activation of fibrinolytic pathways (to enable plasmin to
dissolve fibrin strands in the course of wound healing). In
addition, thrombin interacts with other non-haemostatic systems
to promote cellular chemotaxis, fibroblast growth, angiogenesis,
and wound repair.
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Figure 2 (A) Cumulative incidence of recurrent VTE during anticoagulant therapy among patients with and without cancer. (B) Cumulative incidence of
bleeding during anticoagulant therapy among patients with and without cancer (Prandoni et al, 2002).
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Figure 3 A simplified overview of the haemostatic cascade (Colman, 2006).
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Figure 4 (Colman, 2006). The major role of the coagulation cascade
is the production of fibrin – the meshwork that holds together the
clot – which is produced through a cleavage of fibrinogen by
thrombin. Coagulation is initiated by tissue damage, exposing the
transmembrane glycoprotein tissue factor (TF). Tissue factor is
expressed on the subendothelial surface of blood vessels and
is normally exposed only when normal vasculature is disrupted.
Factor VII binds TF, and the TF–factor VII complex directly
activates factor X to factor Xa and some factor IX to factor IXa. In
the presence of factor Xa, tissue factor pathway inhibitor (TFPI)
inhibits further generation of factor Xa and factor IXa. After
inhibition by TFPI, the amount of factor Xa produced is
insufficient to maintain coagulation. Additional factor Xa (which
allows haemostasis to progress to completion) can only be
generated by the factor IX–factor VIII pathway. Enough thrombin
exists at this point to activate factor VIII, and together with factor
IXa (generated by TF–factor VIIa) to further activate factor X.
Factor IX activation is also augmented by thrombin activation of
the factor XI pathway. Without the amplification and consolidat-
ing action of factor VIII/factor IX, there is insufficient generation
of factor Xa to produce sufficient thrombin. When sufficient
thrombin is generated, this endolytic serine protease selectively
cleaves the Arg–Gly bonds of fibrinogen to form fibrin, releasing
fibrinopeptides A and B and so forms the meshwork of the clot.
It is of note that the above physiological description omits the
classic extrinsic pathway (factor VII-TF initiated coagulation to
common pathway at factor X) and intrinsic pathways activated by
factor XII (and through factors XI, IX, and VIII to common
pathway at factor X). Although factor XII has no role in
physiological blood coagulation, it has been considered that it
may have a role in cancer-related thrombosis (see below). Indeed
most, if not all, aspects of the complex integrated haemostatic
system have been considered to function pathologically in the
setting of cancer.
Activation of the haemostatic system in cancer
Multiple pathways are responsible for regulating cancer growth,
progression, and metastasis. Tumour cells (both solid and
haematological) can activate blood coagulation through multiple
mechanisms, including production of procoagulant, fibrinolytic,
and proaggregating activities; release of proinflammatory and
proangiogenic cytokines; and direct interaction with host vascular
and blood cells (e.g., endothelial cells, leukocytes, and platelets)
through adhesion molecules. The link between the haemostatic
system and cancer is shown by a study conducted by Miller et al
(2004), which evaluated haemostatic status every year for 4 years
in a population of approximately 3000 middle-aged men without
cancer. Among patients with the activation of the haemostatic
system (defined as persistent elevation of fibrinopeptide A and
prothrombin fragment 1þ2 levels), total mortality was substan-
tially higher in participants with persistent activation (17.1/1000
person-years) than in patients without activation (9.7/1000 person-
years; P¼0.015). This difference was attributable to an increased
incidence of death from cancers (11.3/1000 vs 5.1/1000 person-
years), primarily due to a three-fold higher mortality from cancers
of the digestive tract (6.3/1000 vs 1.9/1000 person-years).
The majority of patients with cancer has increased levels of
coagulation factors V, VIII, IX, and XI, as well as increased levels
of markers of coagulation activation (e.g., thrombin–antithrom-
bin, prothrombin fragment 1þ2, fibrinopeptide, and D-dimer
(Table 2) (Hoffman et al, 2001). In addition, patients with
disseminated malignancies seem to have a deficient activity of
von Willebrand’s factor-cleaving protease (ADAMTS13), resulting
in unusually large von Willebrand factor multimers, a key adhesive
protein involved in primary haemostasis (Oleksowicz et al, 1999).
Many tumours have been shown to activate blood coagulation
through an abnormal expression of high levels of the procoagulant
molecule TF. In normal vascular cells, expression of TF is normally
not expressed, except when induced by inflammatory cytokines
such as interleukin 1b and tumour necrosis factor a (TNF-a)o rb y
bacterial lipopolysaccharides. In tumour cells, TF is expressed
constitutively. Constitutive activation of the extrinsic pathway has
been shown in patients with cancer. In a study conducted by
Kakkar et al (1995), plasma levels of TF, factor VIIa, factor XIIa,
the thrombin–antithrombin complex, and prothrombin fragments
were elevated in patients with cancer compared with healthy
controls. Tissue factor and factor VIIa levels were both signifi-
cantly higher, suggesting that the extrinsic pathway was strongly
activated. Levels of factor XIIa were only slightly elevated,
suggesting that the intrinsic pathway is not involved to a
significant extent in the hypercoagulable state seen in patients
with cancer (Rickles and Brenner, 2008).
Tumour cells express cancer procoagulant, a cysteine protease
expressed only on malignant tissue. Cancer procoagulant directly
activates factor X independently of factor VII (Falanga and
Gordon, 1985). Its activity seems to be driven by the stage of
cancer, in that onset of disease is associated with high levels of
activity that slowly declines thereafter (Mielicki et al, 1999).
In addition to the expression of TF and cancer procoagulant,
tumour cells enhance coagulation in patients with cancer by
expressing proteins that regulate the fibrinolytic system, including
plasminogen activators, plasminogen activator inhibitors 1 and 2,
and plasminogen-activator receptor, leading to an imbalance of
fibrinolysis (Prandoni et al, 2005). Tumour cells may elicit platelet
activation and aggregation through direct cell–cell interactions or
through the release of soluble mediators, including ADP,
thrombin, and other proteases. Furthermore, expression of certain
cytokines by tumour cells, including TNF-a and interleukin 1b,
Injury
VIIa
TF
TFPI
Va
Fibrinogen
Prothrombin
Xa
X
IX IX
XIa
XI
Thrombin
activation
Thrombin
Fibrin
IXa
VIIIa
Figure 4 The coagulation cascade (Colman, 2006).
Table 2 Changes in haemostasis due to malignancy
Changes that increase
bleeding Changes that increase thrombosis
Platelet dysfunction Platelet activation
Dysproteinemias Direct factor X activation by TF and other
proteases
Thrombocytopenia Reduced hepatic anticoagulant synthesis
Reduced hepatic clotting
factor synthesis
Decreased hepatic clearance of activated factors
Isolated factor defects Autoimmune phenomena (e.g., lupus
anticoagulant (APL))
Autoimmune phenomena
(e.g., inhibitors)
Adapted from Hoffman et al (2001).
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downregulates the expression of thrombomodulin, resulting in a
prothrombotic milieu at the vascular wall (because of reduced
protein-C activation).
As noted in the Introduction, multiple studies have provided
considerable evidence for a two-way clinical association between
VTE and cancer, in that cancer elicits expression of procoagulant
activities, contributing to the prothrombotic state in these patients,
and the procoagulant activities themselves seem to elicit cancer
growth, proliferation, and metastasis. Fibrin and platelet deposi-
tion around solid tumours promotes angiogenesis through
platelet-derived proangiogenic factors, and may seal immature
tumour vasculature and provide a degree of immunological
‘invisibility’. Fibrin has been shown to induce expression of IL-8
and VEGF – thereby enhancing angiogenesis – and to increase
expression of TF (Qi and Kreutzer, 1995; Fernandez et al, 2004).
The TF–factor VIIa complex can signal through cleavage of
protease-activated receptors, which in turn induce the mitogen-
activated protein kinase (MAPK) signal transduction cascade (Rao
and Pendurthi, 2005). The MAPK pathway, in turn, is involved in
the induction of genes involved in angiogenesis, migration, and
proliferation. In addition, phosphorylation of the cytoplasmic tail
of the TF receptor has also been shown to indirectly activate
transcription of VEGF, downregulate thrombospondin (an anti-
angiogenic protein), and induce cell migration. Expression of TF
by malignant cells also seems to support metastatic success and is
dependent on the formation of the TF–factor VIIa complex.
DISCUSSION
Faculty: A major question is whether the poor survival in patients
is due to more aggressive tumours or whether it is mortality due to
thrombotic events.
John Pasi: Absolutely. It is likely to be both. The data we have
now are superficial, in that they do not separate these 2 factors.
Faculty: Are the mechanisms underlying VTE similar across all
tumour types? Is there a difference between how gastrointestinal
malignancies activate haemostatic pathways compared with breast
cancer?
John Pasi: Different elements are expressed in different tissues.
Some of the broad mechanisms are going to be common across all
tumour types. Haematological malignancies are clearly different in
the way that they induce thrombosis. I suspect that there will be
broad common themes, but there will be a different emphasis on
elements of the coagulation system across tumours.
Faculty: There are some data suggesting that different histolo-
gical types of lung cancer – for example, adenocarcinomas – are
more strongly associated with VTE.
John Pasi: Yes, some of the metastatic non-small-cell lung
cancers produce large amounts of TF, which will drive the
coagulation process in this case.
Faculty: The rates of thromboembolism clearly vary among
tumour types and histologies. This is explained partly by the
ability of the tumour to generate procoagulants and partly by host
factors. As much as the risk for thromboembolism is driven by the
tumour itself, there are features of the individual patient that drive
risk for VTE. For example, patients who are more debilitated will
be less mobile or the anatomical site of the tumour may compress
great veins. The interaction between these and other factors will
determine risk for VTE.
Faculty: Is there a scoring system that can be applied?
Faculty: A validated scale is not available. One scoring system has
been derived from the Neupogen registry. There was a retrospective
analysis of this scoring system, which scored tumours by site, platelet
count, haemoglobin, and other risk factors. If the score was 0, 1, or 2,
the risk of VTE in the first 3 cycles of chemotherapy was very low. If
the score was 3 or greater, the risk for VTE during early cycles was
approximately 7%. The problem with this scoring system is that it
only measures risk in a very specific patient population – one that was
q u i t eu n w e l la n di m m o b i l e .
Faculty: Many oncologists do not systematically search for
thrombosis. There is the possibility that if an effort is made to
screen patients extensively for thrombosis, more will be found and
patients may receive unwarranted treatment. If you take 100
cancer patients and you screen them extensively for thrombosis,
what would you find?
John Pasi: I believe we do not have precise estimates in patients
with cancer, but anecdotally, we frequently see asymptomatic
emboli when patients are undergoing CT or other diagnostic
procedures.
Faculty: We do not know if these incidental thrombi will
influence outcomes.
John Pasi: But you can suggest that the incidental finding of
thrombus may predict recurrence, therefore identifying patients at
risk.
Faculty: I think that is an interesting question. Are those
incidental thrombi truly asymptomatic? There is some work in the
United States that suggests that about 60% of patients in whom
you find an incidental pulmonary embolus will have symptoms of
pulmonary emboli, if questioned carefully. These symptoms may
be masked by the underlying cancer or its treatment, or the fact
that these patients are not active.
Faculty: Is it worthwhile to treat asymptomatic emboli?
John Pasi: It depends on how you extrapolate the data. If you
extrapolate the data that symptomatic presentation is associated
with a higher rate of recurrence, asymptomatic presentation could
equally be associated with significant rate of recurrence. And
therefore, you could argue that it is worth treating it. The question
is whether there is any evidence for treating asymptomatic emboli
– it would make for an interesting study.
Faculty: The problem is that treatment increases the risk for
major bleeding. The risk of major bleeding, even with 6 months of
anticoagulation, is approximately 5%, and this is associated with a
substantial risk for death. If the pulmonary embolism has no
symptoms and we treat it, we will be causing harm in a certain
number of patients. I do not think this is an issue that will be
solved without further study, but for now I believe that the correct
assumption is they should be treated, with the strong caution that
there is a lack of evidence.
Faculty: As an oncologist, are you identifying more venous
thrombosis than you were earlier in your career?
Faculty: Yes.
Faculty: Is that because of diagnostic advances as opposed to a
true increase in the rate of VTE?
Faculty: Lung cancer patients have symptoms that are similar to
PE, so in many cases symptoms will be masked. In the past, only a
small percentage of lung cancer patients received a CT scan. Now,
almost all receive a CT scan. So of course you will pick up more PE.
Faculty: I think that’s right. The genera lc o n s e n s u si st h a t6 4 - s l i c e
CT scanning is probably the biggest reason for identifying more
thrombosis in cancer patients. If you go to historic postmortem series
from the 1930s, for instance, there was a huge incidence of thrombosis.
And if you’re looking at a series in the 1960s and 1970s in Scandinavia,
between 30 and 60% of patients with malignant disease had evidence
of pulmonary embolism at the time of death. Whether that was
contributory or the main cause of death or whether it contributed to
death is not entirely clear. The question is, on a relative basis, how
important is VTE in cancer patients? I think it probably is important,
but data are lacking.
CONSENSUS STATEMENT
Venous thromboembolism is a common occurrence within the
cancer population, and the thrombotic risk due to the tumour itself
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surgery. However, the cancer population is markedly heterogeneous,
with a broad array of histologies, stages, and therapeutic interven-
tions. Consequently, the risk for VTE varies among patients with
cancer. Thus, priority should be placed on the development of a
cancer-specific risk assessment tool to identify those who would
benefit most from thromboprophylaxis. There is very little evidence
to inform the use of thromboprophylaxis in the ambulant, non-
hospitalised cancer patients, particularly those receiving chemother-
apy. This area is in need of additional investigation.
As imaging techniques improve, asymptomatic small-volume
VTE is being diagnosed more frequently in staging scans. There is
little evidence to guide best management in this situation; for
example, whether these events should be treated – or if left
untreated, there is little evidence to suggest that it affects outcome.
This clearly warrants further investigation, although it may pose
practical and ethical challenges in terms of study design.
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